These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1411 related articles for article (PubMed ID: 21189140)

  • 1. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.
    Darwich AS; Neuhoff S; Jamei M; Rostami-Hodjegan A
    Curr Drug Metab; 2010 Nov; 11(9):716-29. PubMed ID: 21189140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate.
    Abuasal BS; Bolger MB; Walker DK; Kaddoumi A
    Mol Pharm; 2012 Mar; 9(3):492-504. PubMed ID: 22264132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs.
    Galetin A; Hinton LK; Burt H; Obach RS; Houston JB
    Curr Drug Metab; 2007 Oct; 8(7):685-93. PubMed ID: 17979656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs.
    Dahan A; Amidon GL
    Mol Pharm; 2009; 6(1):19-28. PubMed ID: 19248230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting intestinal transporters for optimizing oral drug absorption.
    Varma MV; Ambler CM; Ullah M; Rotter CJ; Sun H; Litchfield J; Fenner KS; El-Kattan AF
    Curr Drug Metab; 2010 Nov; 11(9):730-42. PubMed ID: 21189135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P-glycoprotein increases portal bioavailability of loperamide in mouse by reducing first-pass intestinal metabolism.
    Dufek MB; Knight BM; Bridges AS; Thakker DR
    Drug Metab Dispos; 2013 Mar; 41(3):642-50. PubMed ID: 23288866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the impact of controlled release formulations on oral drug absorption, gut wall metabolism and relative bioavailability of CYP3A substrates using a physiologically-based pharmacokinetic model.
    Olivares-Morales A; Kamiyama Y; Darwich AS; Aarons L; Rostami-Hodjegan A
    Eur J Pharm Sci; 2015 Jan; 67():32-44. PubMed ID: 25444842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution.
    Darwich AS; Pade D; Ammori BJ; Jamei M; Ashcroft DM; Rostami-Hodjegan A
    J Pharm Pharmacol; 2012 Jul; 64(7):1008-24. PubMed ID: 22686346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
    Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
    Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction.
    Shen DD; Kunze KL; Thummel KE
    Adv Drug Deliv Rev; 1997 Sep; 27(2-3):99-127. PubMed ID: 10837554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intestinal first-pass metabolism by cytochrome p450 and not p-glycoprotein is the major barrier to amprenavir absorption.
    Dufek MB; Bridges AS; Thakker DR
    Drug Metab Dispos; 2013 Sep; 41(9):1695-702. PubMed ID: 23821186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico, in vitro and in situ models to assess interplay between CYP3A and P-gp.
    Mudra DR; Desino KE; Desai PV
    Curr Drug Metab; 2011 Oct; 12(8):750-73. PubMed ID: 21568936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of human pharmacokinetics--gut-wall metabolism.
    Fagerholm U
    J Pharm Pharmacol; 2007 Oct; 59(10):1335-43. PubMed ID: 17910807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of Drug or Food with Drug Transporters in Intestine and Liver.
    Nakanishi T; Tamai I
    Curr Drug Metab; 2015; 16(9):753-64. PubMed ID: 26630906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of nonlinear intestinal absorption of CYP3A4 and P-glycoprotein substrates from their in vitro Km values.
    Tachibana T; Kato M; Sugiyama Y
    Pharm Res; 2012 Mar; 29(3):651-68. PubMed ID: 21913031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption--theoretical approach.
    Ito K; Kusuhara H; Sugiyama Y
    Pharm Res; 1999 Feb; 16(2):225-31. PubMed ID: 10100307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative prediction of intestinal metabolism in humans from a simplified intestinal availability model and empirical scaling factor.
    Kadono K; Akabane T; Tabata K; Gato K; Terashita S; Teramura T
    Drug Metab Dispos; 2010 Jul; 38(7):1230-7. PubMed ID: 20354105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of intestinal first-pass drug metabolism.
    Yang J; Jamei M; Yeo KR; Tucker GT; Rostami-Hodjegan A
    Curr Drug Metab; 2007 Oct; 8(7):676-84. PubMed ID: 17979655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption.
    Badhan R; Penny J; Galetin A; Houston JB
    J Pharm Sci; 2009 Jun; 98(6):2180-97. PubMed ID: 18855913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 71.